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Abstract: T-cell prolymphocytic leukemia (T-PLL) is a rare and poor-prognostic mature T-cell leu-
kemia. Recent studies detected genomic aberrations affecting JAK and STAT genes in T-PLL. Due to 
the limited number of primary patient samples available, genomic analyses of the JAK/STAT path-
way have been performed in rather small cohorts. Therefore, we conducted—via a primary-data 
based pipeline—a meta-analysis that re-evaluated the genomic landscape of T-PLL. It included all 
available data sets with sequence information on JAK or STAT gene loci in 275 T-PLL. We eliminated 
overlapping cases and determined a cumulative rate of 62.1% of cases with mutated JAK or STAT 
genes. Most frequently, JAK1 (6.3%), JAK3 (36.4%), and STAT5B (18.8%) carried somatic single-nu-
cleotide variants (SNVs), with missense mutations in the SH2 or pseudokinase domains as most 
prevalent. Importantly, these lesions were predominantly subclonal. We did not detect any strong 
association between mutations of a JAK or STAT gene with clinical characteristics. Irrespective of 
the presence of gain-of-function (GOF) SNVs, basal phosphorylation of STAT5B was elevated in all 
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analyzed T-PLL. Fittingly, a significant proportion of genes encoding for potential negative regula-
tors of STAT5B showed genomic losses (in 71.4% of T-PLL in total, in 68.4% of T-PLL without any 
JAK or STAT mutations). They included DUSP4, CD45, TCPTP, SHP1, SOCS1, SOCS3, and HDAC9. 
Overall, considering such losses of negative regulators and the GOF mutations in JAK and STAT 
genes, a total of 89.8% of T-PLL revealed a genomic aberration potentially explaining enhanced 
STAT5B activity. In essence, we present a comprehensive meta-analysis on the highly prevalent 
genomic lesions that affect genes encoding JAK/STAT signaling components. This provides an over-
view of possible modes of activation of this pathway in a large cohort of T-PLL. In light of new 
advances in JAK/STAT inhibitor development, we also outline translational contexts for harnessing 
active JAK/STAT signaling, which has emerged as a ‘secondary’ hallmark of T-PLL. 
Keywords: JAK; STAT; T-PLL; T-cell leukemia; meta-analysis; STAT5B signaling 
 
1. Introduction 
T-cell prolymphocytic leukemia (T-PLL) is an aggressive malignancy characterized by an expan-
sion of mature T-lymphocytes [1]. Although with an incidence of <2.0/million/year in Western coun-
tries infrequently encountered, T-PLL is the most common mature T-cell leukemia [2]. Patients suf-
fering from T-PLL typically present with exponentially rising white blood cell (WBC) counts accom-
panied by bone marrow (BM) infiltration and splenomegaly, and at lower frequencies by various 
other manifestations such as effusions or in skin [3]. Due to its chemotherapy-refractory behavior, T-
PLL patients have a dismal prognosis with a median overall survival (OS) of <3 years [4–6]. Clinicians 
treating T-PLL face limited therapeutic options, mainly caused by a still incomplete mechanistic dis-
ease concept and, therefore, a rudimentary understanding of targetable vulnerabilities in T-PLL. The 
most potent single substance, the CD52-antibody alemtuzumab, leads to complete remissions in more 
than 80% of patients, however, nearly all eventually relapse (at median already within 12 months) 
[3,4,7]. 
Due to the limited number of primary patient samples available, genomic analyses studying the 
underlying disease mechanisms have been performed in rather small cohorts of T-PLL patients. In 
these studies, the most common molecular features revealed were rearrangements that involve chro-
mosome 14 or X, resulting in juxtaposition of the T-cell leukemia/lymphoma 1A (TCL1A) or Mature T-
cell leukemia 1 (MTCP1) proto-oncogenes to TCRAD gene enhancer elements [8]. The second most 
common lesions are genomic alterations of the tumor suppressor ataxia telangiectasia mutated (ATM), 
found in >85% of cases [9]. In addition to these lesions, activating mutations targeting the Janus kinase 
(JAK)/signal transducer and activator of transcription (STAT) pathway components were identified 
in these series of genomic analyses [9–18]. 
The JAK/STAT pathway is a ubiquitous cytokine-mediated signaling cascade that regulates cell 
proliferation, differentiation, migration, and apoptosis [19]. After recruitment of JAKs (JAK1, JAK2, 
JAK3, TYK2) to cytokine receptors, they phosphorylate STAT proteins (STAT1, STAT2, STAT3, 
STAT4, STAT5A, STAT5B, STAT6), which then bind DNA and regulate target gene transcription [20]. 
Dysregulation of the JAK/STAT axis has been described as a key event in the pathogenesis of various 
hematologic malignancies [21]. Constitutively active JAK/STAT signaling induces T-cell tumors in 
mice [22,23]. Using different sequencing approaches, activating mutations of JAK1, JAK3, and 
STAT5B were identified as the most recurrent genomic aberrations affecting JAK/STAT genes in T-
PLL [9–18]. However, prevalence of gene mutations, information on their allele frequencies, assess-
ment of negative regulators of JAK/STAT signaling, and the phosphorylation status of the most re-
currently affected JAK/STAT proteins vary considerably or are not reported in these studies [9–18]. 
Therapeutic approaches blocking JAK/STAT signaling have so far improved patient outcomes 
predominantly in autoimmune conditions and in graft-versus-host disease [24,25]. JAK inhibitors are 
currently tested for a number of new indications [26]. T-PLL cells have shown a notable in vitro sen-
sitivity towards JAK inhibition, which was not directly linked to the JAK/STAT mutation status 
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[15,16]. First reports present individual clinical activity of tofacitinib (pan JAK inhibitor) and rux-
olitinib (JAK 1/2 inhibitor) in relapsed T-PLL [27,28]. 
Although many studies identified JAK and STAT genes to be commonly mutated in T-PLL, these 
analyses have been performed in rather small cohorts not providing a sufficient dataset to determine 
reliable mutation and variant allele frequencies (VAFs). In addition, the publication overlap of these 
studies was unresolved and a systematic assessment for other potential genomic causes (e.g., copy 
number alterations (CNAs)) has not been performed. 
Here, we conducted a meta-analysis that was supplemented by new primary data, hence provid-
ing the largest cohort to date that evaluated the genomic aberrations affecting JAK/STAT signaling in 
T-PLL. In addition to summarizing information on the functional impact of the most recurrent le-
sions, we propose a model of potential mechanisms leading to constitutive JAK/STAT signaling in T-
PLL cells. 
2. Results 
2.1. Characteristics and Overlaps of Included Studies 
The meta-analysis considered all available publications that have analyzed variants of any JAK 
or STAT gene in cases of T-PLL, regardless of the sequencing approach used (Table S1). Redundantly 
sequenced cases were identified to eliminate overlaps between these 10 studies (Figure 1A). The most 
common sequencing approach was Sanger sequencing (Sanger seq., 7 studies), followed by targeted 
amplicon sequencing (TAS, 5 studies), whole exome sequencing (WES, 4 studies), and whole genome 
sequencing (WGS, 2 studies). JAK3 (n = 272 T-PLL patients), JAK1 (n = 246), and STAT5B (n = 209) 
were predominantly sequenced due to the bias by the targeted approaches. Germline controls were 
sequenced in 53 cases (19.3%). The number of analyzed patients varied from 3 to 71 patients across 
the 10 studies [9–18]. After subtracting all cases reported in more than one study, we identified 275 
unique T-PLL cases as the core cohort. 
Notably, data that were acquired by WGS, WES, and SNP array analysis were re-analyzed as 
primary data in cases, in which raw data were available (WES: 62.2%, n = 46/74 T-PLL patients; WGS: 
50.0%, n = 4/8; SNP arrays: 100.0%, n = 71/71), while data gained through Sanger seq. or TAS were not 
re-evaluated. By re-analyzing the WES and SNP array data through a uniform pipeline, homogeneity 
of the resulting dataset was obtained. JAK1, JAK2, JAK3, TYK2, STAT1, STAT2, STAT3, STAT4, 
STAT5A, STAT5B, and STAT6 are further referred to as ‘any JAK or STAT gene’. 
2.2. Mutations in JAK and STAT Genes are Predominantly Found at Subclonal Levels 
We included T-PLL cases with available data from WGS or WES in order to calculate the fre-
quency of genomic variants in JAK and STAT genes. We identified a cumulative rate of 62.1% (n = 
54/87, Figure 1B) cases with variants in any JAK or STAT gene. The vast majority of them were somatic 
single-nucleotide variants (SNVs) of missense type (96.0%, n = 72/75 of variants detected by 
WGS/WES). The remaining three lesions (4.0%, n = 3/75) were small in-frame deletions in JAK1 or 
JAK3. In the following these SNVs and small in-frame deletions are referred to as ‘mutations’. Somatic 
variants were called and known single nucleotide polymorphisms were filtered out in those tumor 
samples for which a matched germline sample was available. For T-PLL patients with a missing 
germline control (n = 38), we included only those variants which were detected in the WES with 
matched germline samples. JAK3 (34.5%, n = 30/87), STAT5B (25.3%, n = 22/87), and JAK1 (9.2%; n = 
8/87) were the most recurrently mutated genes, while TYK2 (2.3%, n = 2/87), STAT4 (2.3%, n = 2/87), 
and STAT5A (1.1%, n = 1/87) were mutated at lower frequencies. Nine of 87 cases (10.3%) presented 
with mutations affecting two genes that encode for JAK or STAT proteins. Co-occuring (‘double’) 
JAK1 and JAK3 mutations were found in 1.1% of cases (n = 1/87), JAK3 and STAT4 in 1.1% (n = 1/87), 
and JAK1 and STAT4 mutations in 1.1% (n = 1/87); JAK1 and STAT5B in 1.1% (n = 1/87), and JAK3 and 
STAT5B in 5.8% (n = 5/87). Co-occuring JAK1, STAT5A, and STAT5B mutations (‘triple’) were detected 
in one case (1.1%). 
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Figure 1. Meta-analyses of genomic profiling series in T-PLL underscore the high prevalence of mu-
tations affecting JAK and STAT genes. (A) T-PLL patients (n = 275) sequenced for any JAK or STAT 
locus. Horizontal bar chart displays the total number of patients sequenced in each publication. Ver-
tical bar chart indicates the size of intersections between sets of patients analyzed in one or more 
publications. Color-code of vertical bars indicates the number of studies reporting results of the same 
individual case (black: 1; dark-orange: 2; medium-orange: 3; light-orange: 4; light grey: 5). Dot con-
necting lines show the overlapping publications of each intersection. (B) Distribution of JAK/STAT 
mutations (n = 87 T-PLL analyzed by whole genome sequencing (WGS)/whole exome sequencing 
(WES)): in 62.1% of these cases (n = 54) at least one mutation in a gene of the JAK/STAT family was 
found to be mutated. (C) Relative frequencies of hotspot mutations of JAK1, JAK3, and STAT5B (as 
defined by the genomic region containing more than 90% of the respective mutations; n = 275 cases 
analyzed by WGS/WES/targeted amplicon sequencing (TAS)/Sanger sequencing). Every T-PLL case 
that was sequenced for the respective hotspot region of JAK1 (Ex. 14–20), JAK3 (Ex. 11–19), and/or 
STAT5B (Ex. 15–17), was included. (D) Box-whisker charted allele frequencies of missense mutations 
of JAK1, JAK3, and STAT5B (n = 153 T-PLL analyzed by WGS/WES and/or TAS) illustrate a high het-
erogeneity in variant allele fractions, with most lesions detected at lower frequencies (<50%). 
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Next, we calculated frequencies of missense mutations considering the hotspots of JAK1 (Ex. 14–
20), JAK3 (Ex. 11–19), and STAT5B (Ex. 15–17). Hotspot regions were defined as genomic regions 
containing >90% of the respective mutations. By also including cases analyzed by TAS or Sanger seq. 
for the respective hotspot region, we arrived at a larger cohort for these analyses. Based on this, the 
hotspot of JAK1 showed a relative mutation frequency of 6.3% (n = 11/175). For the hotspot of JAK3 
this was 36.4% (n = 75/206) and for the hotspot of STAT5B it was 18.8% (n = 38/202, Figure 1C). 
As already described in smaller cohorts [9,16,18], most of these lesions presented as subclonal 
events with low VAFs (medians: JAK1 6.0%, JAK3 28.5%, STAT5B 19.0%, Figure 1D); however, we 
observed a high heterogeneity in VAFs. Notably, the N642H mutation of STAT5B was observed at a 
VAF of >50% in four cases and the M511I mutation of JAK3 at VAFs >50% in five cases. Note that 
given the data provided in the reports, the percentage of treatment-naïve samples was 72.7%; sequen-
tial samples of individual T-PLL patients were not analyzed here. 
2.3. Missense Mutations in JAK1, JAK3, and STAT5B Cluster Within the Conserved Pseudokinase and SH2 
Domains 
We further assessed the localization of the missense mutations of JAK1, JAK3, and STAT5B (Fig-
ure 2, upper protein schemes) as well as the frequencies of hotspot SNVs in these genes (lower inset). 
To assess the localization of the somatic SNVs of JAK1, JAK3, and STAT5B, we included all T-PLL 
cases which have been sequenced for the whole coding genome by WES or WGS. All T-PLL cases 
which have been sequenced for the respective lesion regardless of the sequencing approach were 
considered to determine the frequencies of hotspot mutations. The pseudokinase domain (JH2 do-
main) of JAK1 was predominantly affected (62.5% of all JAK1 mutations, n = 5/8) with V658F (3.7% of 
all analyzed cases, n = 9/246, regardless of the sequencing approach) as the most prominent lesion 
(Figure 2A). In JAK3, most somatic SNVs were found in the JH2-SH2-linker (69.7% of all JAK3 mis-
sense mutations, n = 23/33 detected missense mutations), followed by the JH2 domain (27.3%, n = 
9/33, Figure 2B). The M511I lesion was the most prevalent lesion in JAK3 (27.2% of all analyzed cases, 
n = 74/272, regardless of the sequencing approach). Almost all missense mutations of STAT5B were 
found in the SH2 domain (96.2% of all STAT5B missense mutations, n = 25/26 detected missense mu-
tations; Figure 2C). N642H (9.6% of all analyzed cases, n = 20/209, regardless of the sequencing ap-
proach), T628S (5.9%, n = 12/202), and Y665F (3.3%, n = 7/209) were the most recurrent mutations 
affecting STAT5B. Remarkably, we did not detect significant differences in the mutation frequencies 
with regard to the sequencing approach (see bars of the lower inset of Figure 2). 
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Figure 2. Missense mutations in JAK1/JAK3/STAT5B genes cluster within the conserved JH2 (pseudo-
kinase) and SH2 domains. Upper protein scheme: gene-wide distribution of missense mutations of 
JAK1 (A), JAK3 (B), and STAT5B (C); n = 87 T-PLL analyzed by WES/WGS, representing the same 
cases as in Figure 1B. Lower inset for each sub-panel A–C: frequencies of hotspot mutations, stratified 
for applied sequencing methods (n = 275 cases analyzed with WES/WGS/TAS/Sanger seq). While JAK1 
and JAK3 were predominately affected by lesions within the pseudokinase domains (JH2) and the 
SH2-JH2 linker regions, STAT5B missense mutations were presented mostly in the SH2 domain. 
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2.4. T-PLL Harboring any JAK or STAT Mutation Show Elevated TCL1A mRNA Level, but Present 
Comparable Clinical Outcomes 
When analyzing associations of JAK and STAT mutations with immunophenotypic and cytoge-
netic data as well with the 18 most prevalent mutations found in T-PLL (as described by Schrader et 
al.[9]), we detected a decreased proportion of T-PLL cells with CD40L expression (p = 0.05, Fisher’s 
exact test, Figure S1A) and an increased proportion of T-PLL cells harboring NOTCH2 mutations (p 
= 0.03, Fisher’s exact test, Figure S1B) in the JAK3 mutated cohort (overview of tested associations is 
provided in Table S2). Notably, T-PLL with any JAK or STAT mutation showed elevated TCL1A 
mRNA levels as compared to patients without any JAK or STAT mutation (fold change (Fc) = 4.1, p = 
0.01, Student’s t-test, Figure 3A), further underlined by an increased proportion of cases harboring 
an inversion 14 (q11q32) in the STAT5B mutated cohort (p = 0.03, Fisher’s exact test, Figure S1C). 
TCL1A mRNA levels were also elevated by just considering JAK3 mutated cases (Fc = 6.5, p = 0.002, 
Student’s t-test, Figure S1D) or STAT5B mutated cases (Fc = 3.6, p = 0.02, Student’s t-test, Figure S1E) 
compared to T-PLL without either mutation, respectively. To assess the functional role of variants in 
JAK or STAT genes in T-PLL patients, we screened for significant associations between somatic 
JAK/STAT SNVs and clinical data, including outcome. For these analyses, we merged clinical infor-
mation from nine studies [9–16,18]. As not all considered publications reported the same set of pa-
rameters, cohort sizes varied between the different analyses. When investigating an association of the 
JAK/STAT mutation status with overall survival, we did not observe differences in OS of T-PLL pa-
tients harboring any JAK or STAT mutation compared to patients without JAK or STAT mutation (p 
= 0.42, log rank test, Figure 3B). In contrast to studies of smaller cohorts [12,16], we could not observe 
a significantly shorter OS of JAK3 mutated T-PLL patients (p = 0.26, log rank test, Figure S2A). Simi-
larly, the JAK3 M511 mutation was not associated with a shorter OS (p = 0.39, log rank test, Figure 
S2B). The OS of patients without any JAK or STAT mutations was comparable to those harboring a 
STAT5B (p = 0.55, log rank test, Figure S2C), STAT5B N642H (p = 0.60, log rank test, Figure S2D), or 
JAK1 (p = 0.54, log rank test, Figure S2E) mutation. Interestingly, the JAK1 L653F mutation status was 
associated with a significantly shorter OS (p = 0.003, log rank test, Figure S2F). In addition, cases with 
a STAT5B Y665F mutation also showed a shorter OS (p = 0.06, log rank test, Figure S2G). However, 
only two patients with a JAK1 L653F mutation or five patients with a STAT5B Y665F mutation were 
included in the ‘mutated’ cohorts, so these results should be interpreted with caution. We did not 
detect any other association of clinical characteristics of T-PLL patients with the presence of JAK or 
STAT mutations (Table S3). 
 
Figure 3. JAK/STAT mutation status shows association with elevated TCL1A mRNA expression, but 
not with patient outcomes. (A) TCL1A mRNA expression measured by array-based gene expression 
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profiling (GEP) of JAK/STAT mutated cases compared to cases without any JAK or STAT mutation 
(fold change: 4.1; p = 0.01, Student’s t-test). (B) Overall survival (OS) of JAK/STAT mutated cases (me-
dian OS: 21.0 months) compared to cases without any JAK or STAT mutation (median OS: 25.5 
months, p = 0.42, log rank test). Significant associations between mutations affecting JAK3 or STAT5B 
with immunophenotypic, mutational, and expression data are displayed in Figure S1. Associations of 
mutations affecting JAK1, JAK3, or STAT5B with OS are presented in Figure S2. 
2.5. T-PLL Cells Show Basal STAT5B Phosphorylation, Regardless of Their JAK/STAT Mutation Status 
Even though STAT5B was shown to be predominantly affected in T-PLL in previous series, its 
phosphorylation, and therefore activation state, was often not aligned with the genomic profiling 
data [9–11]. By analyzing primary samples of eight T-PLL cases, we observed noticeable basal 
STAT5B phosphorylation in every case (Figure 4A, no exposure to any culturing). We discovered no 
obvious association between STAT5B phosphorylation and the presence of any JAK or STAT muta-
tion. 
 
Figure 4. T-PLL cells show basal STAT5B phosphorylation, regardless of their JAK/STAT mutation 
status. (A) Elevated basal STAT5B phosphorylation levels of T-PLL cells. Controls: CD3+ pan T-cells 
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isolated from healthy individuals. ‘Loss of neg. reg.’: key regulators which negatively affect STAT5B 
activation (namely DUSP4, CD45, TCPTP, SHP1, SOCS1, SOCS3, and HDAC; see (D) for case-wise 
depiction) were considered based on available literature and based on data of their copy number 
alterations (CNA) in T-PLL. (B) Distribution of genomic lesions affecting any JAK or STAT gene and 
their regulators (n = 49 cases analyzed with WES/WGS and with SNP arrays). Inner pie chart: distri-
bution of JAK/STAT mutations. Outer pie chart: Prevalence of genomic lesions of regulators activating 
JAK/STAT (either genomic losses of negative regulators or genomic gains of positive regulators). An 
overall proportion of 89.8% of T-PLL cases carried a genomic lesion potentially explaining constitu-
tive STAT5B activation (mutation or CNA of JAK/STAT regulator). (C) Prevalence of the five most 
common genomic lesions affecting negative regulators of the JAK/STAT pathway (n = 49 cases ana-
lyzed with WES/WGS and SNP array): T-PLL cases without any mutation in a JAK or STAT gene 
showed a higher prevalence of genomic losses of DUSP4, CD45, and HDAC9 as compared to 
JAK/STAT mutated cases. (D) Mapped genomic events involving JAK and STAT genes and their reg-
ulators (n = 49 cases analyzed with WES/WGS and SNP array). An overview of genomic lesions re-
sulting in a suggested activation of the JAK/STAT pathway across all considered T-PLL cases is given 
in Figure S3. 
Samples without JAK or STAT mutation showed similar levels of high basal phospho-STAT5B 
to those that harbored such lesions, as already previously shown in a series of 6 T-PLL cases [9]. 
We further correlated the immunoblot data with alterations involving key regulators of STAT5B 
activity (either mutations or CNAs). For this, we pre-selected a set of 105 genes encoding for proteins 
known to regulate JAK/STAT signaling based on available literature (Table S4). We next identified of 
these 105 genes 7 which showed recurrent genomic lesions in the overall T-PLL cohort and which 
were reported to have a regulatory effect on STAT5B signaling in vitro or in vivo (Table S5). Overall, 
we identified recurrent mutations or genomic losses of seven negative regulators potentially leading 
to constitutive STAT5B activity (DUSP4, CD45, TCPTP, SHP1, SOCS1, SOCS3, and HDAC9) in 71.4% 
of analyzed T-PLL cases (n = 35/49 cases analyzed with WES/WGS and SNP array, Figure 4B). About 
68.4% of T-PLL cases that did not reveal a mutation in any JAK or STAT gene showed such a CNA of 
a STAT5B signaling regulator. This resulted in a total of 89.8% of T-PLL cases that harbor a genomic 
lesion potentially explaining constitutive STAT5B signaling (either genomic losses of negative regu-
lators, and/or mutations of JAK or STAT genes). Gene expression signatures (array-based) of cases 
that harbor a genomic loss or a mutation of a negative regulator of JAK/STAT signaling (and that lack 
a JAK or STAT mutation) were comparable to those of cases with a mutation in any JAK or STAT gene 
(principal component analysis in Figure S4A). Both cohorts showed similar activation (as per upreg-
ulated gene expression) of STAT5B target genes. All T-PLL with a mutation in a JAK or STAT gene 
and 90% of patients with a mutation or loss in a negative JAK/STAT regulator (and without any mu-
tation in a JAK or STAT gene) showed overexpression of at least one STAT5 target gene. In contrast, 
the frequency of overexpressed STAT5 target genes was significantly lower in T-PLL without a ge-
nomic lesion potentially activating JAK/STAT signaling (60%, Figure S4B). In detail, DUSP4, CD45, 
SOCS3, SHP1, and HDAC9 showed the highest prevalences of genomic losses with a higher frequency 
in T-PLL cases without any JAK or STAT mutation (Figure 4C). In addition, we identified genomic 
gains of STAT2 (n = 1/49 T-PLL), STAT3, (n = 5/49 T-PLL), STAT5A (n = 5/49 T-PLL), and STAT5B (n 
= 5/49 T-PLL). These lesions were detected only in combination with mutations of a JAK or STAT gene 
or with genomic losses of a negative regulator of STAT5B signaling (Figure 4D). 
Overall, we propose a model of constitutive JAK/STAT signaling induced by mutations of a pre-
dicted gain of function (GOF) in JAK1, JAK3, and STAT5B genes and by copy-number losses of nega-
tive regulators of STAT5B activity. 
3. Discussion 
Here, we present a comprehensive meta-analysis of primary data from 275 T-PLL cases from 10 
published studies that evaluated genomic lesions involving elements of JAK/STAT signaling. In this 
large cohort, we identified genomic aberrations potentially leading to constitutive JAK/STAT signal-
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ing in approximately 90% of cases, thus establishing this as a molecular hallmark of T-PLL. Our anal-
ysis provides an overview on the genomic causes of JAK/STAT signaling activation including 
JAK/STAT GOF mutations as well as CNAs of JAK/STAT genes or negative regulators of JAK/STAT 
signaling. 
About 62% of T-PLL cases showed GOF mutations affecting any JAK or STAT gene, while pre-
vious publications reported a mutation frequency varying between 36% and 76% [10,18]. In accord-
ance with these studies, we predominantly detected missense mutations in the SH2 or pseudokinase 
domains of JAK1, JAK3, and STAT5B, mostly occurring at a subclonal level. Mutations of genes en-
coding for components of the JAK/STAT pathway are frequently found in T-cell neoplasms (predom-
inantly mutations of JAK3, STAT3, and STAT5B). Their reported incidences range from 10% (e.g., for 
Sézary syndrome [29]) to 70% (e.g., for intestinal T-cell lymphoma [30]). Compared to those, the cu-
mulative mutation frequency of JAK and STAT genes in T-PLL documented in this meta-analysis is 
high [31]. 
Another important finding was the high basal phosphorylation of STAT5B in all analyzed T-PLL 
samples. In addition to a high proportion of T-PLL cases mutated in any JAK or STAT gene, we iden-
tified seven negative regulators to be commonly lost in T-PLL, potentially explaining cytokine-inde-
pendent STAT5B activation. This affected 71.4% of all cases and 68.4% of those cases without a de-
tectable JAK/STAT SNV. Of these negative regulators, DUSP4, SOCS3, and CD45 were most fre-
quently affected. While genomic losses of DUSP4 and SOCS3 were already reported in primary T-
PLL [9,17,18], losses of CD45 have not been described previously. Compared to CD4+ T-cells isolated 
from healthy individuals, DUSP4 and CD45 mRNA was observed to be strongly downregulated in 
T-PLL cells [16]. Furthermore, the downregulation of CD45 transcripts was associated with an in-
creased phosphorylation of STAT5, implicating a functional relevance of this negative regulator [17]. 
T-PLL cells usually show a complex karyotype and a high frequency of somatic CNAs [9,32]. In 
detail, the loci of the negative regulators DUSP4 (chr.8p12) and of SOCS3 (chr.17q25.3) are known to 
be highly affected by structural aberrations in T-PLL. Therefore, a secondary origin of the detected 
CNAs due to background imbalances has to be considered. T-PLL cases already harboring an acti-
vating mutation of a JAK or STAT gene or a genomic loss of a negative regulator showed in few cases 
(12.2%) also genomic gains of JAK or STAT genes, however, the functional impact of these genomic 
gains remains unclear. 
Certainly, there is the possibility of other, yet-unknown regulators, which we did not include in 
our analysis. Furthermore, our analysis did not assess for epigenetic regulations or post-translational 
modifications of JAK and STAT genes or their regulators, as further causes of active JAK/STAT sig-
naling. Moreover, constitutive T-cell-receptor or cytokine input of the malignant T-cell may represent 
other modes of (milieu-derived) JAK/STAT activation in T-PLL. 
Another important result of the provided meta-analyses is the first description of elevated 
TCL1A in JAK and STAT mutated T-PLL. TCL1A overexpression is known to be associated with ele-
vated levels of reactive oxygen species (ROS) [33]. In addition, an 8-oxoguanine DNA damage signa-
ture is characteristic for T-PLL, likely resulting from ROS-mediated DNA insults [9]. In this context, 
the initiating oncogene TCL1A is likely to contribute to the occurrence of new mutations, especially 
when the guardian of genome-integrity ATM is deleted or mutated, potentially explaining a higher 
prevalence of arising subclonal JAK and STAT mutations in T-PLL. Furthermore, a possible explana-
tion for the association of reduced CD40L expression with the presence of JAK3 mutations is a state 
of less T-cell receptor and cytokine dependent activation of T-PLL cells in the context of an acquired 
hyperactivating mutation of a signaling intermediate such as JAK3. 
In line with our finding, that nearly every T-PLL case presents with a genomic aberration that 
potentially causes activated JAK/STAT signaling, we could not observe any differential association 
of the JAK/STAT mutation status with clinical characteristics, i.e., those indicating a more aggressive 
phenotype of T-PLL cells. Previous studies on small cohorts have shown a negative influence of the 
presence of JAK3 mutations on OS [12,16]. However, as these studies used JAK3 wild type T-PLL as 
a control group, they potentially included patients with mutations of other JAK or STAT genes, there-
fore not representing a proper control. 
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Although functional validations of the herein described genomic aberrations is outside the scope 
of this work, mechanistic analyses of many of the detected genomic aberrations and of their impact 
on tumorigenesis have been performed in various other entities. Such functional findings of muta-
tions of JAK1, JAK3, and STAT5B are summarized in the following (an overview of literature is pro-
vided in Table S5). 
JAK1, the third most frequently mutated JAK or STAT gene in this meta-analysis, showed a cu-
mulative hotspot mutation rate of 6.3% in our analysis, in line with the mutation rates calculated in 
previous studies. V658F, the most prevalent lesion affecting JAK1 in T-PLL, was initially described in 
the development of T-ALL [34]. The V658F lesion is homologous to the JAK2 V617F mutation and 
was shown to lead to constitutive active JAK1 signaling in a cell line model [35]. Cells harboring the 
respective lesion presented enhanced basal JAK1, STAT5, and ERK phosphorylation and showed cy-
tokine-independent growth [36]. S7031 and L653F, less frequently detected JAK1 mutations, were also 
proven to act as GOF mutations [37,38]. While the S703I mutation was shown to mediate proliferative 
effects in vitro and in vivo, the L653F mutation is predicted to soften the negative regulation of JAK1 
in a biophysical model. The JAK1 V617F, S703I, and L653F mutations potentially mediate cytokine-
independent phosphorylation of STAT5B in T-PLL. 
JAK3 mutations were the most recurrent genomic aberration affecting JAK/STAT genes in this 
meta-analysis with a hotspot mutation rate of 36.4% (literature: 21% [12]–71% [17]). The oncogenic 
potential of the most frequent JAK3 mutation M511I as well as the less frequently occurring mutations 
A573V and V674A was shown in various systems: M511I, A573V, as well as V674A mutant cell lines 
demonstrated high phosphorylation of STAT5 and ERK, leading to cytokine independent growth 
[39,40]. When transplanting mice with bone marrow progenitor cells harboring the M511I or A573V 
mutation in JAK3, they develop a T-ALL-like disease, characterized by an expansion of immature 
CD8+ T-cells. In contrast, mice transplanted with V674A mutant bone marrow progenitor cells pre-
sented severe lymphadenopathy and splenomegaly without a significant increase of the WBC count 
[41]. The mentioned JAK3 mutations were also described in T-ALL [42]. The Q507P mutation, the 
third most frequent genomic aberration affecting JAK3 in T-PLL, was not discovered in other entities 
and has so far not been investigated for its functional relevance. 
In this analysis, 18.8% of T-PLL cases were mutated within the hotspot region of STAT5B, while 
the mutation rate in the literature varied from 7% [16] to 36% [10]. The most frequently found N642H 
mutation is a well described GOF mutation: STAT5B N642H transduced cell lines showed prolonged 
phosphorylation and dimerization of STAT5B, resulting in an enhanced transcriptional activity 
[43,44]. The N642H mutation leads to a sustained stability to the anti-parallel dimer as shown by 
crystallization [45]. Transgenic mice harboring the STAT5B N642H lesion rapidly developed aggres-
sive CD8+ T-cell neoplasms [46]. The STAT5B Y665F mutation, which had a notable influence on OS 
of T-PLL patients in our analysis, revealed highly phosphorylated STAT5B, an enhanced transcrip-
tional activity and increased proliferation in a cell culture model, comparable to the STAT5B N642H 
mutation. The above-mentioned genomic aberrations, which have also been described in the muta-
tional landscape of T-LGL [47], may play an important role in the activation of JAK/STAT signaling 
in T-PLL. The functional role of the second most detected STAT5B aberration, the T628S mutation, is 
much less established. This genetic aberration is previously described in hepatosplenic T-cell lym-
phoma and associated with an increased phosphorylation of STAT5 in a cell line model [48]. Notably, 
the three commonly affected JAK/STAT genes (JAK1, JAK3, STAT5B) are crucial for IL-2 signaling, the 
cytokine secreted at highest levels in T-PLL [49]. Targeted approaches in appropriate models have to 
address the chronological role of such lesions as most of them were detected at subclonal levels. 
Given that nearly every T-PLL case harbors a genomic aberration potentially activating 
JAK/STAT signaling, JAK and STAT proteins are clinically relevant targets for T-PLL therapy [50]. 
Interestingly, in a large panel of blood cancers, primary T-PLL patient cells showed high sensitivity 
towards JAK-targeting compounds. Moreover, JAK inhibitors were among the top 25 most effective 
drugs in an ex vivo drug screen of 39 T-PLL patient samples exposed to 301 different substances 
[15,16]. Previous case reports also showed the initial promising results of a combination therapy of 
the JAK inhibitors ruxolitinib (JAK 1/2 inhibitor) and tofacitinib (pan JAK inhibitor) [27,28]. However, 
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previous studies have also argued that the JAK/STAT mutation status alone does not predict ex-vivo 
sensitivity towards JAK inhibitors [16]. This is in line with the observation of multiple, potentially 
distinct mechanisms, apart from missense mutations of JAK/STAT genes, that are required for acti-
vating this pathway. In general, predicting sensitivity of kinase inhibitors often requires larger panels 
of biomarkers, some of which may be outside of the target pathways or direct drivers of the disease. 
Therefore, therapeutic targeting of JAK/STAT signaling has to be expanded on various levels, includ-
ing the development of novel STAT3/5 inhibitors and the extension of pre-clinical and clinical studies 
to large cohorts of T-PLL and other T-cell lymphomas, all with well-characterized tumor material 
(e.g., JAK/STAT activation state). Selective STAT5 inhibitors which bind to the SH2 domain of STAT5 
are currently under development [51]. 
4. Materials and Methods 
4.1. Data Acquisition 
Available literature was systematically screened for all genomic profiling studies that have in-
formation on the mutational status of any JAK or STAT gene in T-PLL, regardless of the sequencing 
technique. We identified a total of 10 publications meeting these criteria (Table S6). Raw data of these 
publications was obtained from different sources, either publicly available or kindly provided by the 
corresponding authors. Full descriptions of the composed data set and detailed information on the 
sources of data are provided in Table S6. Considered T-PLL patients had provided written informed 
consent and all the studies were originally approved by their institutional review boards. 
4.2. Data Merging 
Considering the rarity of T-PLL and the strong collaboration network in T-PLL research, we 
assumed a pronounced exchange of patient samples between different centers and studies. To deter-
mine all redundantly analyzed patients in our cohort, we requested basic patient information to allow 
us to precisely identify potential overlaps while still ensuring anonymity of all the patients (Figure 
1A). In cases where genomic regions were sequenced by different methods, we included the infor-
mation provided by the widest type of analysis, ranking WGS > WES > TAS > Sanger sequencing. In 
total, 275 distinct T-PLL patients were included in our analyses. 
4.3. Raw Data Analysis 
Data acquired through whole-exome sequencing and SNP-array analysis was re-analyzed for 
those cases in which raw data was available, while data obtained through Sanger sequencing or tar-
geted amplicon sequencing was not re-analyzed. Studies where raw data was not available were in-
cluded by applying the already analyzed data. Detailed information on the data sources are listed in 
Table S6 and on the applied tools with references in Table S7. The below subsections describe the 
various genomic analyses performed for the meta-analysis. 
4.3.1. Whole-Exome Sequencing (WES) 
The sequenced raw exome reads were trimmed of B blocks from the end using Trimmomatic 
(RWTH Aachen, Aachen, Germany). The trimmed data were aligned to the human reference genome 
(GRCh build 37) using Burrows Wheeler Aligner (bwa-0.7.12, Wellcome Trust Sanger Institute, Cam-
bridge, UK). After alignment the potential PCR duplicates were removed using Picard (Broad Insti-
tute of Harvard and MIT, Cambridge, MA, USA), and BAM files were generated, sorted, and indexed 
using SAMtools (Wellcome Trust Sanger Institute, Cambridge, UK). Exomic regions were re-aligned 
and the base quality scores were re-calibrated according to the Genome Analysis Toolkit Best Prac-
tices recommendations (GATK 4.1.3.0). VarScan2.2.3 (The Genome Institute, St. Louis, MO, USA) was 
used to call somatic mutations with the following parameters: strand-filter 1, min-coverage-normal 
8, min-coverage-tumor 6, somatic-p-value 0.01, min-var-freq 0.05. The putative somatic mutations 
were annotated for functional consequences using SnpEff 4.03 (Institute of Environmental Health 
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Sciences, Detroit, MI, USA). Variants present in 1000 genome or dbSNP 2.0 Build were filtered out 
from the analysis. 
In order to call somatic single-nucleotide variants in 38 patients without matched germline sam-
ples, MuTect v2 (Broad Institute of Harvard and MIT) was employed with default parameters. Be-
cause we were mostly interested in identifying sequence variants that were likely to contribute to T-
PLL pathogenesis, we focused on those variations that were identified in our analysis of 22 patients 
with matched healthy control samples. Only these filtered mutations have been reported for the pa-
tients without matched germline samples. 
4.3.2. Somatic Copy-Number Alterations (sCNAs) 
Genotyping of Affymetrix GenomeWide SNP6 array (Thermo Fisher Scientific, Waltham, MA, 
USA) was performed using Genotype Console Software 4 (GTC4, Thermo Fisher Scientific) with the 
default parameters using Birdseed v2 algorithms (Broad Institute of Harvard and MIT). In order to 
infer copy number variations in the T-PLL genome, we used the pooled controls as a reference (non-
tumor hematopoietic cell DNA as ‘germline’ from T-PLL patients, n  =  13) created using the GTC 
pipeline. The Canary algorithm was used to call CN state using the default settings in GTC. We per-
formed segmentation analysis on the basis of identified SNPs/CNVs using inbuilt algorithm. Copy 
number values and segmentation were visually assessed in the Integrative Genomics Viewer (Broad 
Institute, Cambridge, MA, USA). Since the segmentation algorithm only reports significantly altered 
segments/regions, we mapped identified genomic regions to genes based on version 75 of the En-
sembl annotation using BiomaRt (version 2.38 and the GenomicRanges R package, version 1.34.0). 
4.3.3. Gene Expression Profiling (GEP) 
The processed normalized expression profiles generated with GenomeStudio were downloaded 
from GEO. Data were merged and adjusted for batch effects using linear regression. A differential 
expression analysis was performed using Student’s t-test on expression values of patients and healthy 
controls (CD3+ pan T-cells from 10 healthy donors). The differentially expressed probes were 
mapped to the respective genes by Illumina provided annotation files. Principal component analysis 
of the whole gene expression set was performed with R. 
4.4. Clinical Data and Statistical Analyses 
All publications were screened for accompanying clinical data and authors were contacted for 
further information. In total, we obtained and merged clinical data from nine publications [9–16,18]. 
For patients who were reported in multiple studies, we included the most detailed clinical data set. 
To assess possible correlations between mutational status and clinical phenotypes, we performed a 
screening approach testing for a broad range of parameters (Table S3), where the patients were strat-
ified by overall mutational status, mutational status of specific genes, and by specific mutations. As 
a control, we used clinical data from T-PLL patients, who were unmutated in all JAK/STAT genes 
analyzed with WES/WGS. 
All statistical analyses were performed using R software and R packages (Table S7). Analysis of 
overall survival, as measured from day of diagnosis until day of event or censoring, was performed 
and graphed with R survival and R survminer packages. Log rank statistics were calculated to test 
for differences in survival distributions. Continuous clinical parameters were tested for normal dis-
tribution with Shapiro–Wilk test and further assessed for their associations to JAK/STAT mutational 
status with either Student’s t-test or Wilcoxon rank sum test, depending on the normality test. Fisher’s 
exact test was used for testing differences in categorical data in patients with JAK/STAT mutations 
compared to unmutated patients. A p < 0.05 was considered to be statistically significant. 
4.5. Immunoblots 
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We performed Western blots of whole-cell lysates of primary T-PLL cells and CD3+ pan T-cell 
isolated from age matched healthy controls by magnetic-bead based cell enrichment. Positive selec-
tion of CD3+ pan T-cells of healthy controls was performed according to the manufactures instruction 
(Biolegend). Following antibodies from Cell Signaling Technology were used in a 1:1000 dilution ac-
cording to the manufacturer’s instruction: phospho-STAT5TYR694 (clone C11C5, catalogue #9359), 
STAT5 (polyclonal, #9363), and GAPDH (clone 14C10, #2118). As a secondary antibody we made use 
of HRP-coupled anti-rabbit (Dianova) in a 1:5000 dilution. Immunoblots were done using Western 
Bright ECL (Advansta, Menlo Park, CA, USA) and luminescence intensities were evaluated by den-
sitometry (ImageJ software, National Institute of Health, Bethesda, MD, USA). Uncropped images of 
the immunoblots are displayed in Figure S5. 
4.6. Data Accessibility 
All genomic data analyzed in this study was gathered from published series. For detailed 
sources of raw data and/or information on JAK/STAT mutations, see Table S6. 
5. Conclusions 
Overall, this meta-analysis provides an overview of the lesional landscape of JAK/STAT associ-
ated genes in the largest cohort of T-PLL cases to date and summarizes the potential functional impact 
of the most common genomic aberrations. Nearly every T-PLL case in our cohort had a genetic aber-
ration, which can be intuitively implicated in constitutively active JAK/STAT signaling. Besides GOF 
missense mutations in JAK/STAT genes, genomic losses of negative regulators of the JAK-STAT sig-
naling axis are frequently found in T-PLL, linking the high basal phosphorylation of STAT5B to ge-
nomic causes. We propose a model for these distinct mechanisms implicated in constitutive STAT5B 
signaling in T-PLL (Figure 5). Our data provide a rational framework for strategies to inhibit 
JAK/STAT signaling in T-PLL, even in patients whose leukemia does not carry mutations in a JAK or 
STAT gene. Development of novel STAT inhibitors and their application, including with synergistic 
partners, in model systems and in T-PLL patients, represent future tasks. 
 
Figure 5. Proposed model of recurrent genomic lesions leading to an enhanced activation of STAT5B 
in T-PLL. Regulatory network summarizing detected genomic lesions (sCNAs, mutations) in 
Positive regulation Negative regulation
Mutation
Genomic loss
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JAK/STAT genes and their direct regulators. Mutations of JAK and STAT genes and genomic losses of 
negative STAT5B regulators being affected in more than 5% of T-PLL patients were included. Fre-
quent missense mutations occur in the JH2 and SH2-JH2 linker of JAK1 and JAK3, potentially leading 
to elevated phosphorylation and dimerization of STAT5B. Activation of JAK1 and JAK3 is potentially 
enhanced through genomic losses (DUSP4, SOCS1, SOCS3, CD45, SHP1, HDAC9, and TCPTP) and 
mutations (HDAC9) of negative regulators. STAT5B activation might be further increased through 
GOF mutations in its SH2 domain. Cytoplasmatic (SHP1, TCPTP) as well as nuclear (DUSP4, HDAC9) 
regulators are commonly affected by genomic losses in T-PLL, leading to intensified STAT5B signal-
ing. Constitutive active STAT5B translocates into the nucleus and regulates transcription of many 
target genes relevant for T-cell development, differentiation, proliferation, migration, and apoptosis 
[52]. 
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T-PLL patients; Figure S3: Overview of genomic lesions associated with an activation of the JAK/STAT pathway 
across all considered T-PLL cases; Figure S4: T-PLL cases harboring any JAK or STAT mutation show similar 
gene expression compared to T-PLL cases with a loss or mutation of a negative regulator potentially activating 
JAK/STAT signaling; Figure S5: Uncropped images of immunoblots; Table S1: Overview of considered publica-
tions; Table S2: Associations of JAK and STAT mutations with immunophenotypic, cytogenetic, and mutational 
data; Table S3: Screening of clinical parameters; Table S4: List of genes encoding for proteins which potentially 
regulate JAK/STAT signaling; Table S5: Overview of references; Table S6: Data sources; Table S7: Bioinformatic 
tools 
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